NCT04444427

Evaluation of GLR2007 for Advanced Solid Tumors

An Open-Label, Multicenter, Phase 1b/2 Study to Establish Safety, Tolerability, and Optimal Dosing Strategy of GLR2007 in Subjects With Advanced Solid Tumors

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 19 (actual)
• Sponsor: Gan and Lee Pharmaceuticals, USA · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Evaluation of GLR2007 for Advanced Solid Tumors

Detailed description

An Open-Label, Multicenter, Phase 1b/2 Study to Establish Safety, Tolerability, and Optimal Dosing Strategy of GLR2007 in Subjects with Advanced Solid Tumors

Conditions

• Non-small Cell Lung Cancer
• Glioblastoma Multiforme

Interventions

Type	Name	Description
DRUG	GLR2007	Administered orally, once daily for 21 days followed by a 7-day treatment holiday.

Timeline

• Start date: 2020-07-15
• Primary completion: 2022-07-29
• Completion: 2022-07-29
• First posted: 2020-06-23
• Last updated: 2022-12-23

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study